Marshall Wace LLP Buys 72,174 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

Marshall Wace LLP boosted its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 1,963.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 75,849 shares of the company's stock after acquiring an additional 72,174 shares during the period. Marshall Wace LLP owned about 0.17% of Apogee Therapeutics worth $3,436,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Alliancebernstein L.P. lifted its holdings in Apogee Therapeutics by 13.5% in the fourth quarter. Alliancebernstein L.P. now owns 1,355,185 shares of the company's stock worth $61,390,000 after acquiring an additional 160,822 shares during the last quarter. Affinity Asset Advisors LLC raised its holdings in shares of Apogee Therapeutics by 40.3% during the fourth quarter. Affinity Asset Advisors LLC now owns 931,728 shares of the company's stock valued at $42,207,000 after buying an additional 267,530 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Apogee Therapeutics by 0.6% during the fourth quarter. Franklin Resources Inc. now owns 866,188 shares of the company's stock valued at $39,238,000 after buying an additional 5,199 shares during the last quarter. Barclays PLC raised its holdings in shares of Apogee Therapeutics by 30.6% during the fourth quarter. Barclays PLC now owns 476,760 shares of the company's stock valued at $21,597,000 after buying an additional 111,714 shares during the last quarter. Finally, Kennedy Capital Management LLC raised its holdings in shares of Apogee Therapeutics by 75.5% during the fourth quarter. Kennedy Capital Management LLC now owns 72,307 shares of the company's stock valued at $3,276,000 after buying an additional 31,113 shares during the last quarter. Institutional investors own 79.04% of the company's stock.

Apogee Therapeutics Trading Down 0.0 %

APGE stock traded down $0.01 during mid-day trading on Tuesday, hitting $37.78. The stock had a trading volume of 366,630 shares, compared to its average volume of 512,742. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -15.61 and a beta of 1.72. The company has a fifty day moving average of $35.23 and a 200 day moving average of $42.52. Apogee Therapeutics, Inc. has a 1-year low of $26.20 and a 1-year high of $63.50.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25). As a group, sell-side analysts expect that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Insider Activity at Apogee Therapeutics

In related news, CEO Michael Thomas Henderson sold 10,000 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total transaction of $301,500.00. Following the completion of the sale, the chief executive officer now owns 1,292,987 shares in the company, valued at $38,983,558.05. This represents a 0.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Carl Dambkowski sold 3,520 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $40.69, for a total value of $143,228.80. Following the completion of the sale, the insider now owns 252,623 shares of the company's stock, valued at $10,279,229.87. This represents a 1.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,970 shares of company stock worth $1,241,701 in the last 90 days. 36.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on APGE. Citigroup began coverage on shares of Apogee Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $95.00 price objective on the stock. Guggenheim restated a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $92.17.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.